Katsiki Niki, Athyros Vasilios G, Karagiannis Asterios, Mikhailidis Dimitri P
Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece, 44, Tsimiski Street, Thessaloniki, 54623, Greece.
Curr Vasc Pharmacol. 2014;12(4):627-41. doi: 10.2174/15701611113119990131.
Metabolic syndrome (MetS), a cluster of dyslipidaemia, central obesity, hypertension and/or insulin resistance, is associated with increased cardiovascular disease (CVD) type 2 diabetes risk. Different diagnostic criteria for MetS have been proposed but in 2009 a joint statement by several scientific societies was released. Apart from the diagnostic criteria, MetS has also been associated with other risk factors including waist to hip ratio, high density lipoprotein dysfunction, small dense low density lipoprotein, postprandial hypertriglyceridaemia, lipoprotein (a), uric acid, liver function tests, prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness, renal dysfunction, nephrolithiasis, polycystic ovary syndrome, obstructive sleep apnea. We discuss the extensive list of MetS-associated factors that may influence vascular risk. Furthermore, we discuss the impact of frequently prescribed drugs (e.g. hypolipidaemic agents) on these variables. These effects may need to be taken into consideration when treating MetS patients.
代谢综合征（MetS）是一组血脂异常、中心性肥胖、高血压和/或胰岛素抵抗，与心血管疾病（CVD）和2型糖尿病风险增加相关。已经提出了不同的MetS诊断标准，但在2009年，几个科学协会发表了一份联合声明。除了诊断标准外，MetS还与其他风险因素相关，包括腰臀比、高密度脂蛋白功能障碍、小而密低密度脂蛋白、餐后高甘油三酯血症、脂蛋白（a）、尿酸、肝功能检查、促血栓形成因素、细胞因子、脂肪因子、维生素D、动脉僵硬度、肾功能障碍、肾结石、多囊卵巢综合征、阻塞性睡眠呼吸暂停。我们讨论了可能影响血管风险的与MetS相关因素的广泛列表。此外，我们讨论了常用药物（如降血脂药物）对这些变量的影响。在治疗MetS患者时可能需要考虑这些影响。
